A Translational Exploration of Anisomelic Acid'S Potential in Reprogramming Tumor Immune Microenvironment (Time) via Regulating Exosomal Biogenesis to Overcome Immune Checkpoint Inhibitor (Ici) Resistance Mediated by Head and Neck Cancer Stem Cells

Our study identifies a novel CMF oncogenic signature as a therapeutic target in HNSCC. It explores anisomelic acid (AA) as a multi-functional agent with the unique ability to target CMF signature, reduce CAF, M2 TAM transformation, in part by negatively impacting the biogenesis of CSC-derived exosomes. By addressing critical ICI resistance and metastasis drivers, this work proposes an innovative strategy that could significantly improve outcomes for HNSCC patients, paving the way for AA as a novel immunotherapeutic agent.